- In January 2024, Merck KGaA entered into a five-year agreement with India's Heavy Water Board (HWB) to locally manufacture deuterated compounds. This collaboration aims to enhance the availability of stable isotope-labeled compounds in India, supporting the growing pharmaceutical and diagnostic sectors.
- In March 2024, Cambridge Isotope Laboratories (CIL) announced the relocation and expansion of its headquarters to Tewksbury, Massachusetts, . This move is designed to enhance the company's operational capabilities and support its growth in the stable isotope-labeled compounds market.
- In January 2022, Merck KGaA announced the expansion of its Stable Isotope Center of Excellence in Miamisburg, Ohio. The new infrastructure increases production capacity of GMP-grade urea-13C Active Pharmaceutical Ingredients, supporting the demand for stable isotope-labeled compounds in clinical diagnostics
- In September 2022, Cambridge Isotope Laboratories (CIL) announced a partnership with ISO topic Solutions to release stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts. These products are designed for use in mass spectrometry lipidomics research and development
- In May 2024, Shimadzu Corporation introduced a new line of stable isotope-labeled compounds designed for enhanced accuracy in mass spectrometry and pharmaceutical research. This launch strengthens Shimadzu’s position in North America, supporting growing demand for precise analytical tools in life sciences and clinical diagnostics.
